#LetsTakeDown6cSellWall, page-335

Pragmatic and reasonable view.

Poor historical stock performance combined with a very tired register is colouring peoples crystal balls...totally understandable.

Autism effects 1.5% of all children globally with only 2 FDA drugs approved to meet this need.
HOPE has taken 20% of the market in PA and generated 7 figures in its first year. The drug works and is clearly welcomed by the Autism community.
That alternative treatment will be available in australia and then Germany with in months.

Insomnia effects so many people globally, treatment options generate BILLIONS a year. Being a sufferer i know doctors DONT like prescribing for it.
Zenivol is clinically prooven to be safer and as effective in treating insomnia and will be available with in this Billion dollar market in months.

With other products on track to tackle old age and the OTC markets again with in coming months...speculative interest may remain sheltered and those crystal balls coloured by such a poor performing investment history .... which is fine.

The point is once the machine gets turned on i dont think people realise the compounding or transformative effect commercialisation of 5 products is going to have ... nor what just the implied ability to licence these drugs in the US will have ... on sentiment.

I dont think people realise once the tap gets turned on even if it starts as a drop ... it doesnt stop ...